NVS Quote, Financials, Valuation and Earnings

AstraZeneca PLC has a net margin of 20.79% compared to Novartis AG's net margin of 10.07%. Novartis AG's return on equity of 27.64% beat AstraZeneca PLC's return on equity of 17.77%.

Novartis AG has a consensus price target of $109.37, signalling downside risk potential of -1.89%. On the other hand AstraZeneca PLC has an analysts' consensus of $85.19 which suggests that it could grow by 15.91%. Given that AstraZeneca PLC has higher upside potential than Novartis AG, analysts believe AstraZeneca PLC is more attractive than Novartis AG.

Novartis AG has a beta of 0.564, which suggesting that the stock is 43.554% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.487%.

Novartis AG has a quarterly dividend of $3.87 per share corresponding to a yield of 3.47%. AstraZeneca PLC offers a yield of 2.11% to investors and pays a quarterly dividend of $1.05 per share. Novartis AG pays 63.85% of its earnings as a dividend. AstraZeneca PLC pays out 65.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are smaller than AstraZeneca PLC quarterly revenues of $14.9B. Novartis AG's net income of $2.8B is higher than AstraZeneca PLC's net income of $1.5B. Notably, Novartis AG's price-to-earnings ratio is 18.96x while AstraZeneca PLC's PE ratio is 32.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.38x versus 4.24x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 20.79% compared to Novartis AG's net margin of 32.59%. Novartis AG's return on equity of 27.64% beat Eli Lilly and's return on equity of 80.24%.

Novartis AG has a consensus price target of $109.37, signalling downside risk potential of -1.89%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 22.35%. Given that Eli Lilly and has higher upside potential than Novartis AG, analysts believe Eli Lilly and is more attractive than Novartis AG.

Novartis AG has a beta of 0.564, which suggesting that the stock is 43.554% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Novartis AG has a quarterly dividend of $3.87 per share corresponding to a yield of 3.47%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.50 per share. Novartis AG pays 63.85% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than Eli Lilly and quarterly revenues of $13.5B. Novartis AG's net income of $2.8B is lower than Eli Lilly and's net income of $4.4B. Notably, Novartis AG's price-to-earnings ratio is 18.96x while Eli Lilly and's PE ratio is 70.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.38x versus 16.58x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 20.79% compared to Novartis AG's net margin of 2.31%. Novartis AG's return on equity of 27.64% beat Pfizer's return on equity of 8.91%.

Novartis AG has a consensus price target of $109.37, signalling downside risk potential of -1.89%. On the other hand Pfizer has an analysts' consensus of $31.26 which suggests that it could grow by 23.36%. Given that Pfizer has higher upside potential than Novartis AG, analysts believe Pfizer is more attractive than Novartis AG.

Novartis AG has a beta of 0.564, which suggesting that the stock is 43.554% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

Novartis AG has a quarterly dividend of $3.87 per share corresponding to a yield of 3.47%. Pfizer offers a yield of 6.67% to investors and pays a quarterly dividend of $0.43 per share. Novartis AG pays 63.85% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Novartis AG quarterly revenues are $13.6B, which are smaller than Pfizer quarterly revenues of $17.8B. Novartis AG's net income of $2.8B is higher than Pfizer's net income of $410M. Notably, Novartis AG's price-to-earnings ratio is 18.96x while Pfizer's PE ratio is 17.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.38x versus 2.27x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of 20.79% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 27.64% beat Roche Holding AG's return on equity of 23.8%.

Novartis AG has a consensus price target of $109.37, signalling downside risk potential of -1.89%. On the other hand Roche Holding AG has an analysts' consensus of $46.29 which suggests that it could grow by 12.49%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Novartis AG has a beta of 0.564, which suggesting that the stock is 43.554% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.111%.

Novartis AG has a quarterly dividend of $3.87 per share corresponding to a yield of 3.47%. Roche Holding AG offers a yield of 3.31% to investors and pays a quarterly dividend of $1.36 per share. Novartis AG pays 63.85% of its earnings as a dividend. Roche Holding AG pays out 92.43% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than Roche Holding AG quarterly revenues of --. Novartis AG's net income of $2.8B is higher than Roche Holding AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 18.96x while Roche Holding AG's PE ratio is 28.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.38x versus 3.77x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.